Please assess the completion status of the following clinical trial:

Trial Title: Imaging Study of Glioblastomas Treated With Avastin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of glioblastoma with clinical or radiological evidence of progression as indicated by the RANO criteria 19~* Previous radiation and temozolomide chemotherapy~* Patients must be receiving Avastin chemotherapy as second-line treatment if in the Avastin group~* Study-specific consent~Exclusion Criteria:~* Failure to meet inclusion criteria~* Pregnant or lactating patients~* Allergy to iodine or CT contrast precludes DECT component of study~* Claustrophobia precludes MR Spectroscopy component of study~* Internal metal which would preclude an MRI scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- DECT/MR Spectroscopy +Avastin (Type: ACTIVE_COMPARATOR): -15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
- DECT/MR Spectroscopy no Avastin (Type: ACTIVE_COMPARATOR): 15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1

Based on this trial design, predict the completion outcome and termination type (if applicable).